---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-017353"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2023-06-14T23:59:59+00:00"
generated_at: "2026-06-14T01:32:51.594122+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "low"
source: SEC EDGAR
---

# SAB Biotherapeutics holds virtual R&D Day; reviews platform and recent designations

## Summary
- Presented portfolio update including recent Breakthrough Therapy and Fast Track designations.
- Highlighted programs: influenza, C. diff, type 1 diabetes (SAB-176, SAB-185, SAB-142, SAB-195).
- No new financial guidance, clinical data, or material business changes disclosed.
- Presentation furnished as Exhibit 99.1 but not text-available; summary based on filing narrative.

## SEC filing metadata
- accession: 0001437749-23-017353
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2023-06-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000143774923017353/0001437749-23-017353-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000143774923017353/sabs20230609_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-017353
- JSON: https://secwatch.observer/filing/0001437749-23-017353.json
- Plain text: https://secwatch.observer/filing/0001437749-23-017353.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.